Form 4: Ventyx CSO John Nuss Reports Stock Transactions

Ventyx Biosciences' Chief Scientific Officer, John Nuss, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• John Nuss, Chief Scientific Officer of Ventyx Biosciences, Inc. (VTYX), reported changes in his beneficial ownership.
• On December 17, 2025, 34,930 restricted stock units (RSUs) vested, converting into common stock.
• On December 18, 2025, Nuss sold 12,675 shares of common stock at a weighted average price of $7.7191 per share.
• The sale was conducted to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Nuss beneficially owns 489,481 shares of Ventyx Biosciences common stock.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (RSU vesting and tax-related sale) which are common and expected, neither significantly positive nor negative for the company's fundamentals.

Positives

• The vesting of restricted stock units indicates continued employee retention and alignment of interests with shareholders.

Negatives

• Insider selling, even for tax purposes, can sometimes be perceived negatively by the market, though this specific sale is for tax obligations.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

This is an insider transaction, a routine event for executives receiving equity compensation, and does not directly reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The reported transactions are standard for executives in publicly traded companies across various industries who receive equity compensation in the form of restricted stock units. It is common practice for a portion of vested shares to be sold to cover tax withholding obligations.

Stakeholder Impact

• Shareholders: Minor impact from routine insider transactions; potential slight dilution from RSU vesting is offset by the tax-related sale.
• Employees: Reinforces the company's equity compensation structure for executives.

Next Steps

• Future RSU vesting events for John Nuss are expected as per the 25% annual vesting schedule, contingent on his continued service.

Key Dates

Recommendation

This Form 4 details routine insider transactions involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common for executives with equity compensation and do not typically signal a change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Ventyx Biosciences, VTYX, John Nuss, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding